Antimicrobial agents in treatment of MRSA infections.
Johnson
Mark D
MD
Decker
Catherine F
CF
D000081:Acetamides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000145:classification / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000453:epidemiology; D017576:Daptomycin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones / Q000627:therapeutic use; D006801:Humans; D000069349:Linezolid; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D008911:Minocycline / Q000031:analogs & derivatives / Q000627:therapeutic use; D023303:Oxazolidinones / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000453:epidemiology*; D017334:Teicoplanin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013754:Tetracyclines / Q000627:therapeutic use; D000078304:Tigecycline; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology; D014640:Vancomycin / Q000627:therapeutic use
D000081:Acetamides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D024841:Fluoroquinolones; D023303:Oxazolidinones; D013754:Tetracyclines; D002981:Clindamycin; C443755:ceftobiprole; D017334:Teicoplanin; D014640:Vancomycin; D000078304:Tigecycline; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; C469289:dalbavancin; D008911:Minocycline; D000069349:Linezolid; D017576:Daptomycin